Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT: A Sub-Analysis of FLAME

(2018) Stefan M Frent et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

(2018) Alberto Papi et al.   LANCET

Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease

(2018) James F. Donohue et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study

(2018) Timm Greulich et al.   International Journal of Chronic Obstructive Pulmonary Disease

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

(2018) Peter M A Calverley et al.   Lancet Respiratory Medicine

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

(2017) Antonio Anzueto et al.   International Journal of Chronic Obstructive Pulmonary Disease

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

(2016) Jadwiga A. Wedzicha et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations

(2016) Clair Clowes et al.   International Journal of Chronic Obstructive Pulmonary Disease

The COPD assessment test and St George's Respiratory Questionnaire: are they equivalent in subjects with COPD?

(2016) Hiroyuki Taniguchi et al.   International Journal of Chronic Obstructive Pulmonary Disease

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

(2016) Dave Singh et al.   International Journal of Chronic Obstructive Pulmonary Disease

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

(2015) R. Buhl et al.   THORAX

A score to predict short-term risk of COPD exacerbations (SCOPEX)

(2015) Barry Make et al.   International Journal of Chronic Obstructive Pulmonary Disease

Minimum clinically important difference for the COPD Assessment Test: a prospective analysis

(2014) Samantha S C Kon et al.   Lancet Respiratory Medicine

Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE study

(2013) Eric D. Bateman et al.   EUROPEAN RESPIRATORY JOURNAL

Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease

(2013) Loes Bertens et al.   International Journal of Chronic Obstructive Pulmonary Disease

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

(2013) Jadwiga A Wedzicha et al.   Lancet Respiratory Medicine

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

(2010) John R. Hurst et al.   NEW ENGLAND JOURNAL OF MEDICINE